CA2112195A1 - Agent de prevention et de traitement de l'arteriosclerose - Google Patents

Agent de prevention et de traitement de l'arteriosclerose

Info

Publication number
CA2112195A1
CA2112195A1 CA002112195A CA2112195A CA2112195A1 CA 2112195 A1 CA2112195 A1 CA 2112195A1 CA 002112195 A CA002112195 A CA 002112195A CA 2112195 A CA2112195 A CA 2112195A CA 2112195 A1 CA2112195 A1 CA 2112195A1
Authority
CA
Canada
Prior art keywords
arteriosclerosis
glimepiride
pharmaceutical composition
preventing
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002112195A
Other languages
English (en)
Inventor
Yusuke Satoh
Toshifumi Inami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Yusuke Satoh
Toshifumi Inami
Hoechst Japan Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yusuke Satoh, Toshifumi Inami, Hoechst Japan Limited filed Critical Yusuke Satoh
Publication of CA2112195A1 publication Critical patent/CA2112195A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002112195A 1992-12-28 1993-12-22 Agent de prevention et de traitement de l'arteriosclerose Abandoned CA2112195A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34747692A JP3465247B2 (ja) 1992-12-28 1992-12-28 動脈硬化症の予防および治療剤
JP347476/92 1992-12-28

Publications (1)

Publication Number Publication Date
CA2112195A1 true CA2112195A1 (fr) 1994-06-29

Family

ID=18390484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002112195A Abandoned CA2112195A1 (fr) 1992-12-28 1993-12-22 Agent de prevention et de traitement de l'arteriosclerose

Country Status (12)

Country Link
US (1) US5416105A (fr)
EP (1) EP0604853A3 (fr)
JP (1) JP3465247B2 (fr)
KR (1) KR940013503A (fr)
CN (1) CN1104888A (fr)
AU (1) AU666992B2 (fr)
CA (1) CA2112195A1 (fr)
HU (1) HUT69398A (fr)
IL (1) IL108197A0 (fr)
NO (1) NO934832L (fr)
PL (1) PL301653A1 (fr)
ZA (1) ZA939707B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631275A (en) * 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
WO1997002036A1 (fr) * 1995-06-30 1997-01-23 Zymogenetics, Inc. 4-(2-(n-(-2-carboxamidoindole)aminoethyl)-benzenesulfamides ou sulfonylurees utilises comme antagonistes du pdgf
KR100413745B1 (ko) * 1995-08-30 2004-03-20 정규범 컨버터스위치의스위칭손실및노이즈저감회로
MXPA04007183A (es) * 2002-01-25 2006-03-06 Silanes Sa De Cv Lab Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
WO2005027981A1 (fr) 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Imagerie de cellules beta cibles du pancreas fondee sur un mecanisme, et therapie associee
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
DE102005034484A1 (de) * 2005-07-20 2007-02-01 Alfred E. Tiefenbacher Gmbh & Co.Kg Verfahren zur Herstellung von Glimepirid enthaltenden pharmazeutischen Zusammensetzungen
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4411903A (en) * 1980-08-11 1983-10-25 American Cyanamid Company 4-[(Monosubstituted-alkyl)amino]benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents
CA1339784C (fr) * 1988-06-23 1998-03-31 Shinya Inoue Derives de l'acide pyrrolecarboxylique

Also Published As

Publication number Publication date
IL108197A0 (en) 1994-04-12
JP3465247B2 (ja) 2003-11-10
CN1104888A (zh) 1995-07-12
NO934832D0 (no) 1993-12-27
JPH06192088A (ja) 1994-07-12
US5416105A (en) 1995-05-16
EP0604853A2 (fr) 1994-07-06
AU5270693A (en) 1994-07-07
HUT69398A (en) 1995-09-28
PL301653A1 (en) 1994-07-11
NO934832L (no) 1994-06-29
HU9303758D0 (en) 1994-04-28
AU666992B2 (en) 1996-02-29
EP0604853A3 (en) 1994-08-24
KR940013503A (ko) 1994-07-15
ZA939707B (en) 1994-08-29

Similar Documents

Publication Publication Date Title
CA2328730C (fr) Traitement de l'hypertension iatrogene et liee au vieillissement et compositions pharmaceutiques utiles a cet effet
EP0336851B1 (fr) Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique
KR100479968B1 (ko) 위장 리파아제 억제제의 용도
US6511985B1 (en) Combination of cerivastatin and fibrates
AU666992B2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
JPH0140009B2 (fr)
NL8000140A (nl) Glycerylfosforylderivaten en teepassing daarvan als geneesmiddel.
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
JPH07103019B2 (ja) 胃炎治療・予防剤
JPH01186883A (ja) 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン
JPS624229A (ja) 鎮痛及び消炎作用を有する医薬
GB2197198A (en) Analgesic preparations
US4156003A (en) Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPS63198630A (ja) 脂質代謝改善剤
JPH09227371A (ja) 粥状動脈硬化抑制剤
DK164021B (da) Anvendelse af diltiazem til fremstilling af et farmaceutisk praeparat til behandling af hyperlipidemi
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
EP0163258A2 (fr) Application de dihydroergotamine
KR920003580B1 (ko) 동맥경화증 예방 및 치료제
US4716177A (en) Tolrestat for inhibition of weight gain
FR2504008A1 (fr) Preparation pharmaceutique a base d'un melange de n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine et d'un diuretique
JPS63107925A (ja) 動脈硬化症予防・治療剤
EP1893208B1 (fr) Composition pharmaceutique comprenant une 1-(3-chlorophenyl)-3-alkylpiperazine pour traiter les troubles de l'alimentation
IE43955B1 (en) Pharmaceutical composition and dosage units thereof

Legal Events

Date Code Title Description
FZDE Discontinued